SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann, Hannah Kleine‐Weber, Simon Schroeder, Nadine Krüger, Tanja Herrler, Sandra Erichsen, Tobias S. Schiergens, Georg Herrler, Nai‐Huei Wu, Andreas Nitsche, Marcel A. Müller, Christian Drosten, Stefan Pöhlmann
Topics & Concepts
TMPRSS2ProteasesBiologyViral entryVirologyCoronavirusProteaseReceptorSerine proteaseSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Priming (agriculture)Protease inhibitor (pharmacology)BetacoronavirusCoronavirus disease 2019 (COVID-19)VirusImmunologyViral replicationGeneticsViral loadEnzymeMedicineDiseaseBiochemistryPathologyGerminationBotanyInfectious disease (medical specialty)Antiretroviral therapySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesViral Infections and Outbreaks Research